LENZ THERAPEUTICS, INC. Sale of Stock, Consideration Received on Transaction
LENZ THERAPEUTICS, INC. (LENZ) had Sale of Stock, Consideration Received on Transaction of $30.00 million as of 2024-07-17, per its 10-K filed 2025-03-19.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-03-24
- 2024-07-17: Sale of Stock, Consideration Received on Transaction $30.00M.
- 2024-03-21: Sale of Stock, Consideration Received on Transaction $53.50M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2024-07-17 | $30.00M 10-K · filed 2025-03-19 |
| 2024-03-21 | $53.50M 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |